Outpatient transcranial magnetic stimulation therapy (TMS) for progressive supranuclear palsy (PSP)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030943

Enrollment

Registered

2024-05-10

Start date

2023-03-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G23.1

Interventions

Group 1: TMS-verum Group 2: sham

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of PSP with decreased stance and gait insecurity.

Exclusion criteria

Exclusion criteria: Contraindications for TMS therapy.

Design outcomes

Primary

Measure	Time frame
Evidence of improvement in gait and stance on the last day of TMS treatment using PosturoMed, Timed up and go and 8 meter walking test.	—

Secondary

Measure	Time frame
Evidence of improvement in general symptoms measured by PSP Rating Scale.	—

Countries

Germany

Contacts

Public ContactOliver Kaut

SRH Gesundheitszentrum Bad Wimpfen

oliver.kaut@srh.de+497063/52-2234

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026